Myovant Sciences Ltd.
(NYSE : MYOV)

( )
MYOV PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.45%185.151.2%$602.67m
CELGCelgene Corporation
-0.43%78.801.2%$532.62m
GILDGilead Sciences, Inc.
-0.63%71.070.9%$518.63m
BIIBBiogen Inc.
-0.44%296.041.2%$437.32m
NKTRNektar Therapeutics
-5.39%52.855.6%$412.99m
SRPTSarepta Therapeutics, Inc.
-6.23%140.3316.6%$356.37m
VRTXVertex Pharmaceuticals Incorporated
1.67%159.191.9%$269.27m
REGNRegeneron Pharmaceuticals, Inc.
0.89%331.972.6%$248.01m
ILMNIllumina, Inc.
-1.19%282.653.5%$212.82m
BLUEBluebird Bio, Inc.
-9.85%168.9015.7%$194.29m
EXASExact Sciences Corporation
-3.62%66.3325.4%$180.98m
AAgilent Technologies, Inc.
-0.40%62.791.5%$178.44m
ALXNAlexion Pharmaceuticals, Inc.
1.40%127.572.0%$159.93m
BMRNBioMarin Pharmaceutical Inc.
0.61%99.034.4%$141.99m
INCYIncyte Corporation
2.12%74.032.5%$133.28m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.